이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

아프리카의 재발 뇌졸중 방지를위한 실로 스타 졸 (CLARITY-Africa)

2026년 11월 10일 업데이트: Bruce Ovbiagele, Northern California Institute of Research and Education

Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

1100

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Kumasi, 가나
        • Kwame Nkrumah University of Science & Technology
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

30년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Above the age of 30 years; male or female (sex is a biological variable of interest)
  2. Ischemic stroke or high-risk TIA (ABCD2 score >= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
  3. Aspirin or clopidogrel monotherapy
  4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension >140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
  5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them
  6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
  7. Able to do labs at all study intervals (7 visits total)

Exclusion Criteria:

  1. Unable to provide a valid informed consent
  2. Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.)
  3. Hemorrhagic stroke survivor within the last 2 years
  4. Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation)
  5. On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy)
  6. Modified Rankin Scale 5
  7. Thrombocytopenia (platelet count <1000,000)
  8. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
  9. Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity)
  10. Nursing/pregnant mothers

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cilostazol Experimental Arm

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

간섭 없음: Control Arm

Standard of post-stroke care

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
주요한 심혈관 사건을 가진 참가자의 비율
기간: 36 개월
36 개월

2차 결과 측정

결과 측정
측정값 설명
기간
주요 출혈 및 경미한 출혈 참가자의 비율
기간: 24 개월
24 개월
재발 성 뇌졸중 참가자의 비율 (허혈 또는 출혈성)
기간: 24 개월
24 개월
심혈관 사망 참가자의 비율
기간: 24 개월
24 개월
모든 원인 사망률을 가진 참가자의 비율
기간: 24 개월
24 개월
Neuro-QoL (Quality of Life)
기간: 24 months

12 monthly

Neuro-QoL uses T-scores, which are standardized scores:

Mean (average) = 50 Standard deviation = 10

Interpreting T-scores:

Scores 0.5 - 1.0 SD worse than the mean = mild symptoms/impairment Scores 1.0 - 2.0 SD worse than the mean = moderate symptoms/impairment Scores 2.0 SD or more worse than the mean = severe symptoms/impairment

For negative domains (e.g. anxiety, depression, fatigue):

Higher = Worse

We will compare mean Neuro-QoL scores between the two arms of the study at study completion as well as proportions with mild, moderate and severe impairment.

24 months
Exploratory outcomes Montreal Cognitive Assessment
기간: 24 months

6 monthly. Comparison of Slopes of MOCA scores over 24 months. Range of scores on MOCA: 0 to 30.

MOCA screening tool is used to detect mild cognitive impairment and early signs of dementia. It evaluates several cognitive domains, including:

Memory Attention Language Visuospatial skills Executive function Orientation

A score of 26 or above is considered normal. Scores below 26 may suggest cognitive impairment, depending on education level and clinical context.

24 months
Quality of Life (EQ-5D Questionnaire)
기간: 24 months

The EQ-5D is a health-related quality of life questionnaire with two parts:

Descriptive system: Assesses 5 dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on 3 or 5 levels (from no problems to extreme problems).

Visual Analog Scale (VAS): Rates overall health from 0 (worst) to 100 (best).

Scoring:

The 5-digit health state is converted into a summary index score (range: <0 to 1), with 1 = full health.

The VAS reflects the person's self-rated health.

We will compare scores between the two arms at study completion.

24 months
Modified Rankin Score
기간: 24 months

The Modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities after a stroke or other neurological injury.

Scoring:

0 - No symptoms

  1. - No significant disability; able to carry out all usual activities
  2. - Slight disability; unable to do all previous activities but able to look after own affairs
  3. - Moderate disability; needs some help but can walk unassisted
  4. - Moderately severe disability; unable to walk or attend to bodily needs without help
  5. - Severe disability; bedridden, incontinent, requires constant care
  6. - Dead
24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 1일

기본 완료 (추정된)

2029년 7월 31일

연구 완료 (추정된)

2029년 8월 31일

연구 등록 날짜

최초 제출

2025년 3월 17일

QC 기준을 충족하는 최초 제출

2025년 4월 2일

처음 게시됨 (실제)

2025년 4월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 24-41599

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant level data will be aggregated and maintained as de-identified to protect PHI

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .